BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $30 from $33 and keeps a Buy rating on the shares. The firm updated its model for fiscal Q1 financials, calling the quarterly update “mainly a reiteration of timelines for key R&D programs.” Following the update, the firm pushed back the MG and CIDP launches to 2027-plus to reflect 1402 trial timelines, the analyst noted.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant price target lowered to $37 from $40 at JPMorgan
- Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
- Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
- Immunovant Reports Progress and Financial Results
- Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating